GB830426A - Self-propelling pharmaceutical compositions - Google Patents

Self-propelling pharmaceutical compositions

Info

Publication number
GB830426A
GB830426A GB7565/57A GB756557A GB830426A GB 830426 A GB830426 A GB 830426A GB 7565/57 A GB7565/57 A GB 7565/57A GB 756557 A GB756557 A GB 756557A GB 830426 A GB830426 A GB 830426A
Authority
GB
United Kingdom
Prior art keywords
inhalant
medicament
acid
alcohol
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB7565/57A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Riker Laboratories Inc
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Publication of GB830426A publication Critical patent/GB830426A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An inhalant preparation comprises an inhalant medicament dissolved in an aerosol propellant which is a halogenated lower alkane containing at least 1 fluorine atom, such as an appropriate "Freon" (Registered Trade Mark), and which constitutes 50 to 90% by weight of the preparation. A co-solvent such as a lower alcohol or emer may be used, as may stabilizers or antioxidants such as alkali-metal bisulphites or ascorbates, ascorbic acid, nordihydroguaiaretic acid, 2- or 3-tertiarybutyl-4-hydroxy anisole, butylated hydroxytoluene or ethyl hydro-caffeate. The medicament may be a vasoconstrictive amine or its acid addition salts, hormones, enzymes, alkaloids, steroids, analgesics, bronchodilators, antihistamines, antitussives, anginal preparations, antibiotics and sulphonamides, such as isoproterenol hydrochloride [a - (isopropljaminomethyl) protocatechuyl alcohol], phenylephrine, epinephrine, ephedrine, narcotine, nicotine, codeine, atropine, ergotamine, scopolamine, colchicine, cortisone and alkyl nitrites such as amyl or octyl nitrite.
GB7565/57A 1956-03-21 1957-03-07 Self-propelling pharmaceutical compositions Expired GB830426A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572788A US2868691A (en) 1956-03-21 1956-03-21 Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Publications (1)

Publication Number Publication Date
GB830426A true GB830426A (en) 1960-03-16

Family

ID=24289356

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7565/57A Expired GB830426A (en) 1956-03-21 1957-03-07 Self-propelling pharmaceutical compositions

Country Status (3)

Country Link
US (1) US2868691A (en)
BE (1) BE555319A (en)
GB (1) GB830426A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216794A (en) * 1988-03-22 1989-10-18 Fisons Plc Aerosol comprising solution of inhalation medicament

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051621A (en) * 1959-10-22 1962-08-28 Grove Lab Inc Gel composition, pressurized container with same, and method of preparation
US3050443A (en) * 1960-02-16 1962-08-21 James F Schuyler Headache remedy containing ammonia
NL262354A (en) * 1960-03-17
US3039928A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable aqueous isoproteronol compositions
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
BE632504A (en) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL302251A (en) * 1963-01-28 1965-10-11
US3710782A (en) * 1969-10-01 1973-01-16 Hauser Res And Eng Co Method of treating human skin with a composition for electromedical applications
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4576949A (en) * 1984-05-07 1986-03-18 The Upjohn Company Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
EP0213108A3 (en) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmaceutical preparation containing an antihypotonic as the active agent
JPH0645538B2 (en) * 1987-09-30 1994-06-15 日本化薬株式会社 Nitroglycerin spray
FR2625677A1 (en) * 1988-01-07 1989-07-13 Cosnier Alain Medicinal composition intended for administration in aerosol form
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
MX9203481A (en) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg FORMULATIONS.
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
EP0518601A1 (en) 1991-06-10 1992-12-16 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
EP0616525B1 (en) * 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
CA2125666C (en) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
ATE204743T1 (en) * 1991-12-18 2001-09-15 Minnesota Mining & Mfg AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ATE177941T1 (en) * 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma STABILIZED MEDICAL AEROSOL SOLUTIONS
EP0632008B1 (en) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
ATE164834T1 (en) * 1993-12-03 1998-04-15 Ono Pharmaceutical Co AMIDINOPHENOL DERIVATIVES WITH PHOSPHOLIPASE A2 INHIBITORY EFFECT
NZ276637A (en) * 1993-12-20 1997-07-27 Minnesota Mining & Mfg Aerosol containing flunisolide, ethanol, and tetrafluoroethane and/or heptafluoropropane propellant
EP0703216B1 (en) 1994-09-20 1999-04-07 Ono Pharmaceutical Co., Ltd. Amidinophenol derivatives as protease inhibitors
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
KR980009238A (en) 1995-07-28 1998-04-30 우에노 도시오 Sulfonyl amino acid derivative
KR100231230B1 (en) * 1995-08-08 1999-11-15 우에노 도시오 Hydroxamic acid derivatives useful for inhibiting gelatinase
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DK1014943T3 (en) 1997-02-05 2002-10-14 Jago Res Ag Medical aerosol formulations
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US7153866B1 (en) * 1997-05-27 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JPH11187882A (en) 1997-12-26 1999-07-13 Ono Pharmaceut Co Ltd Novel polypeptide, its production, cdna coding for the same polypeptide, vector comprising the same cdna, host cell transformed by the same vector, antibody of the same polypeptide, and pharmaceutical composition containing the polypeptide of antibody
NZ509328A (en) 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
ATE234604T1 (en) 1998-08-04 2003-04-15 Jago Res Ag MEDICAL AEROSOL FORMULATIONS
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
IL159996A0 (en) 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003070707A1 (en) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
KR20050045946A (en) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
WO2004002531A1 (en) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
DE10161767T1 (en) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotentiating compositions containing an anti-PD-L1 antibody
JP4691988B2 (en) 2002-10-03 2011-06-01 小野薬品工業株式会社 LPA receptor antagonist
WO2004032964A1 (en) * 2002-10-10 2004-04-22 Ono Pharmaceutical Co., Ltd. Remedies for allergic diseases
ES2584606T3 (en) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microspheres comprising ONO-1301
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
MXPA05009771A (en) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient.
WO2004092169A1 (en) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
US20050107306A1 (en) * 2003-05-16 2005-05-19 Barr Philip J. Treatment of respiratory disease associated with matrix metalloproteases by inhalation of synthetic matrix metalloprotease inhibitors
US20050069918A1 (en) * 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
EP1661580B1 (en) 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
KR20110140139A (en) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Compound capable of binding s1p receptor and pharmaceutical use thereof
ES2425746T3 (en) 2003-09-01 2013-10-17 Ono Pharmaceutical Co., Ltd. Condensed cyclic compound and use thereof
US20080118442A1 (en) * 2003-09-10 2008-05-22 Map Pharmaceuticals, Inc. Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation
CN1870976A (en) * 2003-10-20 2006-11-29 先灵公司 Pharmaceutical compositions
EP1698375B1 (en) 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
EP3115057B1 (en) 2004-10-21 2019-09-04 ONO Pharmaceutical Co., Ltd. Use of immunesuppressant receptor
MX2007005845A (en) * 2004-11-24 2007-07-04 Alcon Inc Method of delivering nasal spray.
WO2006084041A2 (en) 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing diabetes
PT1901749T (en) 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
HUE054887T2 (en) * 2005-06-17 2021-10-28 Wisconsin Alumni Res Found Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
JP5251127B2 (en) 2005-10-28 2013-07-31 小野薬品工業株式会社 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
US20090281120A1 (en) 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
JPWO2007069671A1 (en) 2005-12-15 2009-05-21 小野薬品工業株式会社 Bicyclic heterocyclic compounds
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2008097664A1 (en) * 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
DE102008007198A1 (en) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral or nasally administrable formulations containing epinephrine with improved properties
ES2809177T3 (en) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalation of levofloxacin to reduce lung inflammation
JP2012505223A (en) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド Aerosol fluoroquinolone formulation for improved pharmacokinetics
TWI469965B (en) 2008-12-22 2015-01-21 Ono Pharmaceutical Co Ethynylindole compounds
US8569504B2 (en) 2009-06-17 2013-10-29 Ono Pharmaceutical Co., Ltd. Imidazopyridine compound
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
CA2773033C (en) 2009-09-04 2016-10-11 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
RU2560147C2 (en) 2010-06-21 2015-08-20 Оно Фармасьютикал Ко., Лтд. Novel crystalline forms of 4,4'-[4-fluoro-7({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl} ethynyl)-2-methyl-1h-indole-1,3-diiyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid and 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl) butoxy]phenyl} ethynyl)-1h-indole-1,3-diiyl]dibutanoic acid
TWI534125B (en) 2010-12-02 2016-05-21 Ono Pharmaceutical Co Novel compounds, salts thereof or solvates thereof, and pharmaceutical compositions and pharmaceutical products containing the same
ES2913095T3 (en) 2011-01-31 2022-05-31 Avalyn Pharma Inc Aerosolized pirfenidone and pyridone analog compounds and uses thereof
WO2012127885A1 (en) 2011-03-18 2012-09-27 小野薬品工業株式会社 Tetrahydrocarboline derivative
TW201350479A (en) 2012-04-26 2013-12-16 Ono Pharmaceutical Co TrK inhibitor compound
SG11201506514QA (en) 2013-02-19 2015-09-29 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2015115673A1 (en) 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
US20200016255A1 (en) 2016-11-30 2020-01-16 Sumitomo Dainippon Pharma Co., Ltd. Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (en) 2017-03-30 2020-02-13 大日本住友製薬株式会社 WT1 cancer antigen peptide and peptide conjugate containing the same
EP3679932A1 (en) 2017-09-06 2020-07-15 ONO Pharmaceutical Co., Ltd. METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
MX2020012939A (en) 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarker for judging efficacy of immune checkpoint inhibitor.
SG11202103573YA (en) 2018-10-11 2021-05-28 Ono Pharmaceutical Co STING Agonistic Compound
CN114206386A (en) 2019-08-05 2022-03-18 小野药品工业株式会社 Determining biomarkers for effectiveness of immune checkpoint inhibitors
JPWO2021107125A1 (en) 2019-11-29 2021-06-03
WO2021205631A1 (en) 2020-04-10 2021-10-14 小野薬品工業株式会社 Sting agonistic compound
WO2021230247A1 (en) 2020-05-12 2021-11-18 大日本住友製薬株式会社 Pharmaceutical composition for treating cancer
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2022251679A1 (en) 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222976A (en) * 1937-11-15 1940-11-26 Sharp & Dohme Inc Nasal drops
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2216794A (en) * 1988-03-22 1989-10-18 Fisons Plc Aerosol comprising solution of inhalation medicament
GB2216794B (en) * 1988-03-22 1991-11-20 Fisons Plc Pharmaceuticals compositions

Also Published As

Publication number Publication date
BE555319A (en) 1900-01-01
US2868691A (en) 1959-01-13

Similar Documents

Publication Publication Date Title
GB830426A (en) Self-propelling pharmaceutical compositions
GB994734A (en) Self-propelling powder-dispensing compositions
ES2178817T3 (en) AEROSOL MEDICINAL FORMULATIONS.
IE37201B1 (en) Substituted piperidinoalkanone oxime derivatives
US3282781A (en) Inhalant compositions
CA2355651A1 (en) Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide
ATE204474T1 (en) MEDICINAL PRODUCTS CONTAINING AMETHOCAIN
GB1089043A (en) Aerosol compositions containing phenylephrine derivatives
GB889282A (en) Preparation of hexafluorodiethyl ether and medicinal compositions containing it
GB1192853A (en) Inhalation Aerosol Compositions
GB813767A (en) Aerosol compositions
GB1291414A (en) Aerosol composition
ES273809A3 (en) A procedure to produce a measured dosage of aerosol-lied medicine, suitable for inhalation therapeutics (Machine-translation by Google Translate, not legally binding)
IE36952L (en) Aerosol pharmaceutical compositions
GB1235529A (en) Composition for mucolysis
GB977934A (en) Aerosol composition
GB1032961A (en) Anti-static nitro cellulose and acrylic lacquer compositions
AU226290B2 (en) Composition containing an aminobenzodioxane or pharmaceutically acceptable salts thereof as active ingredient adapted for therapeutic administration
CA532212A (en) Pharmaceutical preparation for topical anesthesia and process of administration
GB1479572A (en) Triazolocycloalkahydrothiadiazine derivatives
GB1143440A (en) Inhalation aerosol preparation
GB1522658A (en) Soluble noscapine cough syrup
AU3635658A (en) Composition containing an aminobenzodioxane or pharmaceutically acceptable salts thereof as active ingredient adapted for therapeutic administration
CA534480A (en) Method and composition of producing a fire-extinguishing foam
GB830735A (en) New phenylacetic acid esters, their production and compositions containing them